GIM
KYMR icon

Glenmede Investment Management’s Kymera Therapeutics KYMR Stock Holding History

Glenmede Investment Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$240K Sell
4,241
-740
-15% -$33.4K ﹤0.01% 1201
2025
Q2 		$217K Buy
+4,981
New +$172K ﹤0.01% 1206

Other funds holding KYMR

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Glenmede Investment Management's KYMR Position: Q3 2025 in Review

Glenmede Investment Management reduced its Kymera Therapeutics (KYMR) stake by 15% in Q3 2025, selling an estimated $33.4K and leaving 4,241 shares worth $240K. The position accounts for ﹤0.01% of the portfolio, ranked #1201.

Glenmede Investment Management first reported a position in KYMR in Q2 2025 and has held it in 2 quarters since. 210 funds tracked by Wall St. Rank hold KYMR as of Q3 2025.

  • Glenmede Investment Management held 4,241 shares of Kymera Therapeutics worth $240K as of Q3 2025.
  • Glenmede Investment Management sold 740 Kymera Therapeutics shares in Q3 2025, an estimated $33.4K.
  • Kymera Therapeutics made up ﹤0.01% of Glenmede Investment Management's portfolio in Q3 2025, its #1201 holding.
  • Glenmede Investment Management first reported a position in Kymera Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.